• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Evotec, Eternygen collaborate for novel metabolic disease therapy

Evotec, Eternygen collaborate for novel metabolic disease therapy

May 12, 2014
CenterWatch Staff

Evotec, a drug discovery alliance and development partnership company, and Eternygen, a Berlin-based, privately owned biopharmaceutical company, are collaborating to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and experience in drug discovery and preclinical development.

Eternygen is working on the sodium coupled citrate transporter NaCT, a novel target that is a key regulator of energy metabolism involved in the pathogenesis of fatty liver, diabetes and obesity. NaCT, also known as PMCT or SLC13A5, is a sodium coupled citrate transporter predominantly expressed in liver cells and the mammalian homolog of the INDY (I am not dead yet) gene in Drosophila. NaCT is an attractive therapeutic target for the treatment of non-alcoholic fatty liver disease, obesity and type 2 diabetes by influencing the mammalian energy metabolism.

Evotec will use its best-in-class drug discovery platform to discover and develop a suitable clinical candidate.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing